Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00904540
NCT00904540CompletedPhase 4

Open-Label Study Assessing the Efficacy of Topical Lidocaine Patch in Treatment of Low Back Pain

Endo Pharmaceuticals0 sites131 target enrollmentStarted: March 2002Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 4
Status
Completed
Sponsor
Enrollment
131
Primary Endpoint
Mean change in average daily intensity (Question 5 of Brief Pain Inventory [BPI] Questionnaire) from baseline to Week 2
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Patients with acute or chronic Lower Back Pain (LBP) participated in a Phase IV clinical trial to assess the effectiveness of Lidoderm administered once daily (q24h) for 2 weeks in the treatment of acute and chronic LBP.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Non-radicular LBP pain for
  • •≤12 months (non-radicular defined as LBP that does not radiate below the mid-buttock and with no sensory symptoms in the leg)
  • •Had LBP as the primary source of pain. Patients may have had mild to moderate spinal stenosis and no radicular symptoms
  • •Had an average daily pain intensity score of >4 on a 0 to 10 scale, with 0 being no pain and 10 being pain as bad as the patients have ever imagined (Question 5 of BPI) within 24 hours prior to the screening visit.
  • •Had a normal neurological examination, including:
  • •Motor strength
  • •Sensory testing (light touch, pinprick, and vibration)
  • •Deep tendon reflexes
  • •Patients were eligible for participation in the long-term chronic (>12 months) group of the study if they also:
  • •Had LBP for greater than one year. Patients may have had any of the following: lumbar degenerative disc disease, internal disc disruption, mild-to-severe spinal stenosis, degenerative scoliosis and spondylolisthesis, facet arthropathy

Exclusion Criteria

  • •Had a history of greater than one back surgery or one back surgery within 3 months of study entry
  • •Had severe spinal stenosis and radicular symptoms
  • •Had any other chronic pain condition that, in the opinion of the investigator, would have interfered with patient assessment of LBP relief
  • •Had received an epidural steroid/local anesthetic injection within 2 weeks prior to study entry
  • •Had received trigger point injections within 2 weeks prior to study entry
  • •Had received Botox Injections within 3 months prior to study entry
  • •Were taking a lidocaine-containing product that could not be discontinued while receiving Lidoderm
  • •Were taking class 1 anti-arrhythmic drugs (e.g., mexiletine, tocainide)
  • •Patients were excluded from participation in the long-term chronic (>12 months) group if they also:
  • •Had an undefined spinal diagnosis
  • •Had a history of lumbar spine surgery within 6 months prior to study entry

Arms & Interventions

Lidoderm®

Experimental

Commercially available Lidoderm (lidocaine patch 5%), up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain

Intervention: Lidoderm® (Drug)

Outcomes

Primary Outcomes

Mean change in average daily intensity (Question 5 of Brief Pain Inventory [BPI] Questionnaire) from baseline to Week 2

Time Frame: Visits - V2 (Day 0), V3 (Day 7), V4 (Day 14), V5 (Day 28), V6/EOS (Day 42)

Secondary Outcomes

  • Mean change from baseline to Week 6 in average pain intensity (Question 5 of the BPI)(Visits - V2 (Day 0), V3 (Day 7), V4 (Day 14), V5 (Day 28), V6/EOS (Day 42))
  • Mean change from baseline to Week 2 and to Week 6 in Neuropathic Pain Scale (NPS) composite scores(Visits - V2 (Day 0), V3 (Day 7), V4 (Day 14), V5 (Day 28), V6/EOS (Day 42))
  • QOL: change from baseline to Week 2 to Week 6 in Question 9 of the BPI, in Beck Depression Inventory Questionnaire, and the Patient and Investigator Global Assessment of Patch Satisfaction and Pain Relief(Visits - V2 (Day 0), V3 (Day 7), V4 (Day 14), V5 (Day 28), V6/EOS (Day 42))
  • Safety assessments include AEs, clinical laboratory tests, vital signs, physical/neurological examinations, and dermal/sensory assessments.(Visits - V2 (Day 0), V3 (Day 7), V4 (Day 14), V5 (Day 28), V6/EOS (Day 42))

Investigators

Sponsor
Endo Pharmaceuticals
Sponsor Class
Industry

Similar Trials

Completed
Not Applicable
Pain Response to Open Label Placebo in Induced Acute Pain in Healthy Male AdultsAcute Pain
NCT03361579University Hospital, Basel, Switzerland35
Completed
Not Applicable
Pain Relief in Patients With Chronic Low Back Pain Using HeatTens vs. Standard Care.Chronic Low Back PainMovement Evoked Pain
NCT03643731Vrije Universiteit Brussel50
Unknown
Not Applicable
A Study on the Effectiveness of Tuina in Managing Chronic Low Back PainChronic Low-back Pain
NCT05363579Singapore General Hospital204
Completed
Phase 4
Pilot Study of the Efficacy and Safety of Lidoderm Patch in the Treatment of Low Back PainChronic Low Back Pain
NCT00904475Endo Pharmaceuticals102
Completed
Phase 2
Open-label Placebo in Manual TherapyLow Back Pain, Recurrent
NCT06306742Studio Osteopatico Busto Arsizio31
Topical Lidocaine Patch in Low Back Pain | Clinical Trial